Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Digitalis Investigation Group (DIG) trial: a stimulus for further research.

× No keyword cloud information.

12 in total

1. Therapeutic ranges of serum digoxin concentrations in patients with heart failure.

Authors: Zachary D Goldberger; Ary L Goldberger
Journal: Am J Cardiol Date: 2012-04-11 Impact factor: 2.778

2. Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium.

Authors: R Padrini; M Panfili; G Magnolfi; D Piovan; D Casarotto; M Ferrari
Journal: Br J Clin Pharmacol Date: 1999-11 Impact factor: 4.335

Review 3. To dig or not to dig.

Authors: G R Dagenais; J M Brophy
Journal: Trans Am Clin Climatol Assoc Date: 1998

Review 4. Pharmacological treatment of chronic heart failure.

Authors: Rachele Adorisio; Leonardo De Luca; Joseph Rossi; Mihai Gheorghiade
Journal: Heart Fail Rev Date: 2006-06 Impact factor: 4.214

Review 5. The pump, the exchanger, and the holy spirit: origins and 40-year evolution of ideas about the ouabain-Na⁺ pump endocrine system.

Authors: Mordecai P Blaustein
Journal: Am J Physiol Cell Physiol Date: 2017-11-07 Impact factor: 4.249

6. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

Authors: Nezihi Baris; Sule Kalkan; Sema Güneri; Volkan Bozdemir; Hulya Guven
Journal: Eur J Clin Pharmacol Date: 2006-06-10 Impact factor: 2.953

7. Mice expressing ouabain-sensitive α1-Na,K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy.

Authors: Arshani N Wansapura; Valerie M Lasko; Jerry B Lingrel; John N Lorenz
Journal: Am J Physiol Heart Circ Physiol Date: 2010-10-15 Impact factor: 4.733

Digitalis Investigation Group (DIG) trial: a stimulus for further research.

1. Therapeutic ranges of serum digoxin concentrations in patients with heart failure.

2. Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium.

Review 3. To dig or not to dig.

Review 4. Pharmacological treatment of chronic heart failure.

Review 5. The pump, the exchanger, and the holy spirit: origins and 40-year evolution of ideas about the ouabain-Na⁺ pump endocrine system.

6. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

7. Mice expressing ouabain-sensitive α1-Na,K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy.

8. Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties.

Review 9. Regenerative principles enrich cardiac rehabilitation practice.

Review 10. Cell therapy for cardiac repair--lessons from clinical trials.

Digitalis Investigation Group (DIG) trial: a stimulus for further research.

1. Therapeutic ranges of serum digoxin concentrations in patients with heart failure.

2. Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium.

Review 3. To dig or not to dig.

Review 4. Pharmacological treatment of chronic heart failure.

Review 5. The pump, the exchanger, and the holy spirit: origins and 40-year evolution of ideas about the ouabain-Na+ pump endocrine system.

6. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

7. Mice expressing ouabain-sensitive α1-Na,K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy.

8. Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties.

Review 9. Regenerative principles enrich cardiac rehabilitation practice.

Review 10. Cell therapy for cardiac repair--lessons from clinical trials.

Review 5. The pump, the exchanger, and the holy spirit: origins and 40-year evolution of ideas about the ouabain-Na⁺ pump endocrine system.